Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNASDAQ:DSCI
CUSIP24982750
Phone+1-609-5144744
Debt
Debt-to-Equity RatioN/A
Current Ratio1.29
Quick Ratio1.02
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20.97%
Return on Equity-17.10%
Return on Assets-12.43%
Miscellaneous
Employees263
Outstanding Shares28,340,000
Market Cap$0.00
Derma Sciences (NASDAQ:DSCI) Frequently Asked Questions
What is Derma Sciences' stock symbol?
Derma Sciences trades on the NASDAQ under the ticker symbol "DSCI."
How were Derma Sciences' earnings last quarter?
Derma Sciences Inc (NASDAQ:DSCI) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.16. The medical instruments supplier earned $22.20 million during the quarter, compared to analysts' expectations of $22.40 million. Derma Sciences had a negative return on equity of 17.10% and a negative net margin of 20.97%. View Derma Sciences' Earnings History.
Has Derma Sciences been receiving favorable news coverage?
Headlines about DSCI stock have trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Derma Sciences earned a coverage optimism score of 0.03 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 49.91 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Derma Sciences.
How do I buy shares of Derma Sciences?
Shares of DSCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Derma Sciences' stock price today?
One share of DSCI stock can currently be purchased for approximately $7.00.
How can I contact Derma Sciences?
Derma Sciences' mailing address is 214 Carnegie Ctr Ste 300, PRINCETON, NJ 08540-6237, United States. The medical instruments supplier can be reached via phone at +1-609-5144744.
MarketBeat Community Rating for Derma Sciences (NASDAQ DSCI)
MarketBeat's community ratings are surveys of what our community members think about Derma Sciences and other stocks. Vote "Outperform" if you believe DSCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
